Table 2. Characteristic and outcomes of patients with and without administration of diuretic therapy while on vasopressors after propensity matching.
| No diuretics N = 423 | Diuretic N = 423 | Total N = 846 | P-value | |
|---|---|---|---|---|
| Age–median (IQR) | 69 (61, 78) | 69 (61, 77) | 69 (61, 77) | .11 |
| Gender, F, n (%) | 165 (39%) | 165 (39%) | 330 (39%) | * |
| CKD-EPI eGFR Median (IQR) | 70 (56, 92) | 73 (56, 93) | 71 (56, 92) | .61 |
| Oliguria, n (%) | 214 (51%) | 214 (51%) | 428 (51%) | * |
| Advanced oxygenation therapies, n (%) | 294 (70%) | 294 (70%) | 588 (70%) | * |
| Min Lactate on inclusion | 1.5 (1.2, 1.5) | 1.5 (1.2, 1.5) | 1.5 (1.2, 1.5) | .91 |
| Minimum P/F ratio; Median (IQR) | 191 (140, 191) | 173 (148, 178) | 173 (143, 191) | .061 |
| SOFA Score Median (IQR) | 8 (6, 10) | 8.0 (6, 10) | 8 (6, 10) | .51 |
| APACHE III Score; Median (IQR) | 53 (41, 66) | 54 (39, 68) | 53 (40, 67) | .91 |
| Total Norepinephrine equivalent dose mcg/kg; Median (IQR) Day 1 | 61 (25, 138) | 37 (10, 75) | 47 (18, 111) | < .001 |
| Day 1 fluid balance ml | 2703 (1302, 5028) | -172 (-1609, 1139) | 1215 (-495, 3149) | < .0011 |
| Day 2 fluid balance ml | 480 (-461, 1536) | -84 (-1281, 797) | 182 (-924, 1199) | < .0011 |
| Day 3 fluid balance ml | -116 (-1036, 898) | -250 (-1410, 623) | -198 (-1232, 700) | .031 |
| AKI Stage III Day 0 to 7 n (%) | 66 (16%) | 83 (20%) | 149 (18%) | .12 |
| RRT Day 0 to 7 n (%) | 34 (8%) | 37 (9%) | 71 (9%) | .72 |
1 = Wilcoxon signed-rank test
2 = McNemar's Test
*McNemar's Test not calculated in cases that no discordant pairs were present